Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Most baseline characteristics were well balanced between the two groups (all standardized mean differences [SMDs] < 0.1), except for the use of antidepressants, antiepileptics, and alendronate.Baseline characteristics of study subjects before and after PSM matching (PSM)VariablesBefore PSMaAfter PSMaRomosozumab users(n = 2985)PTH analogs users(n = 3778)SMDRomosozumab users(n = 2258)PTH analogs users(n = 2258)SMDCurrent age, mean ± SD70.9 ± 7.569.3 ± 7.70.20770.1 ± 7.470.1 ± 7.70.007Age at index, mean ± SD68.7 ± 7.566.2 ± 7.70.32667.6 ± 7.367.6 ± 7.60.002Sex, n (%) Female2867 (96.0)3381 (89.5)0.2552173 (96.2)2169 (96.1)0.009 Male30 (1.0)324 (8.6)0.36030 (1.3)33 (1.5)0.011 Unknown gender88 (2.9)73 (1.9)0.06655 (2.4)56 (2.5)0.003Race, n (%) White2339 (78.4)3020 (79.9)0.0391809 (80.1)1826 (80.9)0.019 Unknown race211 (7.1)346 (9.2)0.077173 (7.7)168 (7.4)0.008 Asian292 (9.8)169 (4.5)0.207154 (6.8)144 (6.4)0.018 Other race60 (2.0)137 (3.6)0.09858 (2.6)60 (2.7)0.006 Black or African American63 (2.1)90 (2.4)0.01854 (2.4)51 (2.3)0.009 Native Hawaiian or other Pacific islander13 (0.4)10 (0.3)0.02910 (0.4)10 (0.4)0.000 American Indian or Alaska native10 (0.3)11 (0.3)0.00810 (0.4)10 (0.4)0.000Family history of osteoporosis, n (%)46 (1.5)53 (1.4)0.01142 (1.9)39 (1.7)0.010Social economic status, n (%) Persons with potential health hazards related to socioeconomic and psychosocial circumstances14 (0.5)12 (0.3)0.02410 (0.4)10 (0.4)0.000Lifestyles, n (%) Personal history of nicotine dependence140 (4.7)200 (5.3)0.028108 (4.8)115 (5.1)0.014 Nicotine dependence62 (2.1)135 (3.6)0.09053 (2.3)53 (2.3)0.000 Tobacco use25 (0.8)39 (1.0)0.02019 (0.8)24 (1.1)0.023 Alcohol related disorders12 (0.4)17 (0.5)0.00710 (0.4)10 (0.4)0.000 Reduced mobility18 (0.6)20 (0.5)0.01011 (0.5)13 (0.6)0.012 Difficulty in walking, not elsewhere classified12 (0.4)10 (0.3)0.02410 (0.4)10 (0.4)0.000 Dependence on wheelchair10 (0.3)10 (0.3)0.01310 (0.4)10 (0.4)0.000Medical utilization/procedures, n (%) Office or other outpatient services1893 (63.4)2043 (54.1)0.1911369 (60.6)1339 (59.3)0.027 Preventive medicine services188 (6.3)308 (8.2)0.072167 (7.4)160 (7.1)0.012 Emergency department services98 (3.3)101 (2.7)0.03663 (2.8)63 (2.8)0.000 Hospital inpatient and observation care services40 (1.3)98 (2.6)0.09035 (1.6)39 (1.7)0.014 Surgical procedures on the femur and knee joint13 (0.4)16 (0.4)0.00211 (0.5)10 (0.4)0.007 Surgical procedures on the pelvis and hip joint15 (0.5)26 (0.7)0.02411 (0.5)14 (0.6)0.018 Surgical procedures on the spine12 (0.4)43 (1.1)0.08411 (0.5)10 (0.4)0.007Comorbidities, n (%) Disorders of lipoprotein metabolism and other lipidemias802 (26.9)1014 (26.8)0.001593 (26.3)617 (27.3)0.024 Vitamin D deficiency684 (22.9)956 (25.3)0.056550 (24.4)545 (24.1)0.005 Hypertensive diseases612 (20.5)823 (21.8)0.031457 (20.2)454 (20.1)0.003 Chronic lower respiratory diseases230 (7.7)365 (9.7)0.070177 (7.8)181 (8.0)0.007 Other forms of heart disease198 (6.6)366 (9.7)0.112163 (7.2)180 (8.0)0.028 Diabetes mellitus176 (5.9)284 (7.5)0.065141 (6.2)134 (5.9)0.013 Diseases of arteries, arterioles and capillaries115 (3.9)213 (5.6)0.08499 (4.4)94 (4.2)0.011 Ischemic heart diseases91 (3.0)192 (5.1)0.10376 (3.4)79 (3.5)0.007 Overweight and obesity90 (3.0)145 (3.8)0.04575 (3.3)66 (2.9)0.023 Other rheumatoid arthritis90 (3.0)163 (4.3)0.06975 (3.3)80 (3.5)0.012 Anemia, unspecified85 (2.8)179 (4.7)0.09975 (3.3)73 (3.2)0.005 Chronic kidney disease106 (3.6)133 (3.5)0.00274 (3.3)79 (3.5)0.012 Rheumatoid arthritis with rheumatoid factor71 (2.4)82 (2.2)0.01456 (2.5)59 (2.6)0.008 Diseases of liver67 (2.2)94 (2.5)0.01643 (1.9)47 (2.1)0.013 Cerebrovascular diseases47 (1.6)101 (2.7)0.07640 (1.8)47 (2.1)0.023 Heart failure34 (1.1)75 (2.0)0.06828 (1.2)33 (1.5)0.019 Malnutrition27 (0.9)46 (1.2)0.03123 (1.0)21 (0.9)0.009 Systemic lupus erythematosus22 (0.7)34 (0.9)0.01818 (0.8)18 (0.8)0.000 Unspecified dementia10 (0.3)10 (0.3)0.01310 (0.4)10 (0.4)0.000 Ankylosing spondylitis10 (0.3)11 (0.3)0.00810 (0.4)10 (0.4)0.000Medications, n (%) Corticosteroids for systemic use658 (22.0)920 (24.4)0.055501 (22.2)501 (22.2)0.000 HMG CoA reductase inhibitors471 (15.8)724 (19.2)0.089350 (15.5)435 (19.3)0.099 Antidepressants388 (13.0)749 (19.8)0.185310 (13.7)396 (17.5)0.105 NSAIDs356 (11.9)662 (17.5)0.158294 (13.0)347 (15.4)0.067 Opioids324 (10.9)598 (15.8)0.147280 (12.4)273 (12.1)0.009 Antiepileptics304 (10.2)625 (16.5)0.188241 (10.7)320 (14.2)0.106 Diuretics243 (8.1)399 (10.6)0.083198 (8.8)209 (9.3)0.017 Sex hormones and modulators of the genital system191 (6.4)373 (9.9)0.127166 (7.4)180 (8.0)0.023 Alendronate179 (6.0)300 (7.9)0.076128 (5.7)187 (8.3)0.103 Aspirin113 (3.8)235 (6.2)0.11293 (4.1)109 (4.8)0.034 Antipsychotics97 (3.3)132 (3.5)0.01485 (3.8)59 (2.6)0.066 Calcium84 (2.8)89 (2.4)0.02963 (2.8)50 (2.2)0.037 Zoledronic acid31 (1.0)26 (0.7)0.03827 (1.2)14 (0.6)0.061 Raloxifene27 (0.9)27 (0.7)0.02122 (1.0)14 (0.6)0.040 Risedronate20 (0.7)43 (1.1)0.04918 (0.8)27 (1.2)0.040 Ibandronate19 (0.6)42 (1.1)0.05114 (0.6)23 (1.0)0.044 Calcitonin10 (0.3)10 (0.3)0.01310 (0.4)10 (0.4)0.000Laboratory, n (%) Body mass index (BMI), ≧ 30 kg/m2284 (9.5)395 (10.5)0.031221 (9.8)217 (9.6)0.006 Calcium in serum, < 6.5 mg/dL10 (0.3)10 (0.3)0.01310 (0.4)10 (0.4)0.000 eGFR, < 60 mL/min/1.73 m2423 (14.2)443 (11.7)0.073294 (13.0)287 (12.7)0.009 Phosphate in serum, < 3.5 mg/dL381 (12.8)515 (13.6)0.026290 (12.8)292 (12.9)0.003 Calcidiol in serum, < 30 ng/mL98 (3.3)196 (5.2)0.09586 (3.8)82 (3.6)0.009PSM: propensity score matching, PTH: Parathyroid hormone, SMD: standardized mean difference, SD: standard deviation, HMG CoA: hydroxy-3-methylglutaryl coenzyme A, NSAIDs: anti-inflammatory and anti-rheumatic products, non-steroids, eGFR: Glomerular filtration rate/1.73 sq M. predicted in serum, plasma or blood by creatinine-based formulaIf the patient is less or equal to 10, results show the count as 10Bold font represents a standardized difference was more than 0.1a Propensity score matching was performed on age, sex, race, family history of osteoporosis, social economic status, lifestyles, medical utilization/procedures, comorbidities, medication usage (corticosteroids, sex hormones, opioids), and laboratory results (calcium, phosphate, calcidiol, BMI, and eGFR)

Source: Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a retrospective cohort study using the TriNetX U.S.

Source: Methods.

Therefore, analyses using TriNetX are generally not considered “human subjects research” and are exempt from IRB review.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1 to 34) analogs in women

Cohort study · Biology of Sex Differences · 2026

Original publication title

Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1 to 34) analogs in women

Ko-Hsiu Lu; Shiow-Ing Wang; Shun-Fa Yang

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Compared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.

Source: Background

Abstract: What methods does the paper describe?

A TriNetX cohort study assessed fracture and mortality risks using Kaplan: Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

Source: Methods

Abstract: Results

After propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542 to 0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511 to 0.977) compared with PTH receptor agonists. Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731). Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort.

Source: Results

Abstract: Conclusion

Compared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment.

Source: Conclusion
Authors’ abstract

Background

To compare the effectiveness of romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists [teriparatide (TPTD)/abaloparatide (APTD)] in reducing fracture risk following osteoporosis treatment.

Methods

A TriNetX cohort study assessed fracture and mortality risks using Kaplan: Meier analysis with hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

After propensity score matching (n = 2,258 pairs), ROMO users had lower risks of osteoporotic fractures (HR: 0.711, 95% CI: 0.542 to 0.931) and hypercalcemia (HR = 0.707, 95% CI: 0.511 to 0.977) compared with PTH receptor agonists. Five subgroup analyses demonstrated a reduced fracture risk in the ROMO cohort among women (HR: 0.738), patients aged ≥ 65 years (HR: 0.652), individuals with a history of prior fractures (HR: 0.659), and those without chronic kidney disease (CKD) (HR: 0.731). Sensitivity analyses confirmed the robustness of the findings across different covariate adjustments, data sources, and extended follow-up, consistently showing a lower risk of hypercalcemia and nonsignificant trends toward reduced fracture risk in the ROMO cohort.

Conclusion

Compared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13293-025-00817-1.

Plain language summary

Osteoporosis is a disease that makes bones weak and more likely to break, especially in older adults and women after menopause. This study compared two types of bone-strengthening medicines: romosozumab (ROMO) and parathyroid hormone (PTH) drugs, including teriparatide and abaloparatide. Researchers used a large health database to see which treatment better prevented bone fractures. They found that people taking ROMO had fewer fractures and fewer cases of high calcium levels in the blood than those taking PTH drugs. The benefits of ROMO were strongest in women, people aged 65 and older, and those who had fractures before.

These results suggest that ROMO may offer stronger short-term protection against fractures compared with PTH drugs. However, doctors still need to consider possible side effects and each person’s overall health before choosing the best treatment. This study provides helpful information for patients and doctors in deciding how to manage osteoporosis and reduce the risk of fragility fractures.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13293-025-00817-1.

Highlights

Compared romosozumab (ROMO) with parathyroid hormone (PTH) receptor agonists for fracture prevention in osteoporosis.

ROMO users had lower risks of fractures and hypercalcemia after patient matching.

Benefits were greater in women, adults ≥ 65 years, those with prior fractures, and without kidney disease.

Findings were consistent across data sources and sensitivity analyses.

ROMO offers stronger short-term protection, though safety and treatment sequencing need consideration.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13293-025-00817-1.

Publication and source details

Original title: Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1 to 34) analogs in women

Ko-Hsiu Lu; Shiow-Ing Wang; Shun-Fa Yang

Biology of Sex Differences · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.https://doi.org/10.13039/501100004699Chung Shan Medical University HospitalCSH-2024-D-003

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:41:28.576950+00:00

DOI: 10.1186/s13293-025-00817-1 · PMC12870266